123533-41-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Phenylimidazo[1,2-a]pyridine-3-carboxylic acid is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure and potential biological activities make it a promising candidate for the creation of new drugs with therapeutic benefits.
Used in Chemical Synthesis:
In the chemical industry, 2-Phenylimidazo[1,2-a]pyridine-3-carboxylic acid serves as a key building block for the synthesis of a wide range of chemical compounds. Its versatile structure allows for the formation of various derivatives, expanding its applications in different chemical processes.
Used in Medicinal Chemistry Research:
2-Phenylimidazo[1,2-a]pyridine-3-carboxylic acid is utilized in medicinal chemistry research to explore its potential as a lead compound for the development of new therapeutic agents. Its anti-cancer and anti-inflammatory properties are of particular interest, as they may contribute to the discovery of novel treatments for various diseases.
Used in Agricultural Chemistry:
In agricultural chemistry, 2-Phenylimidazo[1,2-a]pyridine-3-carboxylic acid is employed as a synthetic intermediate for the development of agrochemicals, such as pesticides and herbicides. Its potential biological activities may contribute to the creation of more effective and environmentally friendly agricultural products.

InChI:InChI=1/C14H10N2O2/c17-14(18)13-12(10-6-2-1-3-7-10)15-11-8-4-5-9-16(11)13/h1-9H,(H,17,18)

Upstream product

• 119448-82-7 ethyl 2-phenylimidazo[1,2-a] pyridine-3-carboxylate 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 504-29-0 2-aminopyridine 
• 55919-47-6 ethyl 2-bromo-3-oxo-3-phenylpropionate 

Downstream Products

• 85102-26-7 2,3-diphenyl-1H-imidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS

The present invention is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which

I2O5-Mediated Iodocyclization Cascade of N-(1-Arylallyl)pyridine-2-amines with Concomitant C=C Bond Cleavage: A Synthesis of 3-Iodoimidazo[1,2- a]pyridines

A facile method for the synthesis of 3-iodoimidazo[1,2-a]pyridines has been successfully developed involving an I2O5-mediated iodocyclization cascade of N-(1-arylallyl)pyridin-2-amines with concomitant C=C bond cleavage. Preliminary mechanistic studies reveal that this protocol might undergo an oxidative cyclization/decarboxylation/iodination sequence in which I2O5 is used as both an oxidant and an iodine source. The present protocol has advantages of wide substrate scope, simple operation, and metal-free conditions.

Synthesis and binding affinity of 2-phenylimidazo[1,2-α]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type

A number of 6-substituted or 6,8-disubstituted alkyl 2- phenylimidazo[1,2-a]pyridine-3-carboxylates 5a-h,-acetates 5i-s, 6a-g, and - propionates 5t, 6h and of N,N-dialkyl-2-phenylimidazo[1,2-α]pyridlne-3- carboxamides 7a-d, -aceramides 7e-t or -propionamide 7u were prepared following new synthetic methods, and their affinities for both the central (CBR) and the peripheral (PBR) benzodiazepine receptors evaluated. The compounds of the ester series displayed low affinity for both receptor types. Conversely, most of N,N-dialkyl(2-phenylimidazo[1,2-a]pyridin-3-yl)acetamides 7e-t proved to possess high affinity and selectivity for CBR or PBR depending on the nature of substituents at C(6)- and/or C(8) on the heterocyclic ring system. In particular, the 6-substituted compounds 7f-n displayed ratios of IC50 values (IC50(CBR)/IC50(PBR)) ranging from 0.32 (7m) to 232 (7k), while the 6,8-disubstituted compounds 7o-t were more than 1000-fold more selective for PBR versus CBR. Compounds 7f,m were examined in several different benzodiazepine receptor subtypes. Expression of specific GABA(A) receptor subunit assemblies in Xenopus oocytes was utilized to evaluate functionally both the efficacy and potency of the positive modulation of GABA-evoked C1+ currents by 7f and 7m in comparison with Zolpidem. The rank order of potencies of these drugs was 7f (EC50 = 3.2 x 10-8 M) > Zolpidem (EC50 = 3.6 x 10-8 M) > 7m (EC50 = 2.2 x 10-7 M). The actions of these compounds were also tested on α2β2γ2(s) receptors. However, the EC50 of these compounds was increased, compared to α1β2γ2(s) receptors, by 30-, 4-, and 5-fold for 7m, 7f, and Zolpidem, respectively. Finally, these compounds were almost completely devoid of activity at receptors containing the α5 subunit.